Rare Diseases
Page 2 • 12 itemsGain critical insights into global orphan drug development & rare disease market trends. Stay ahead in pharma R&D, investment, and regulatory strategy.
X4 Pharmaceuticals Receives European Commission Approval for XOLREMDI (Mavorixafor) as First WHIM Syndrome Treatment in EU
X4 Pharmaceuticals announces European Commission approval for XOLREMDI (mavorixafor), the first authorized treatment for WHIM syndrome patients in the EU.
Norgine Receives European Approval for XOLREMDI (Mavorixafor), First WHIM Syndrome Treatment in EU
Norgine's XOLREMDI becomes the first authorized treatment for WHIM syndrome in Europe, marking a breakthrough for ultra-rare immunodeficiency patients.
Norgine Receives European Commission Approval for XOLREMDI (Mavorixafor) as First WHIM Syndrome Treatment
Norgine's XOLREMDI becomes first authorized treatment for WHIM syndrome in Europe, marking breakthrough for ultra-rare immunodeficiency patients.
European Biomarker-Driven Trials: EMA Regulatory Framework & Success Rates
This article delves into the EMA's regulatory framework for biomarker-driven trials, highlighting success rates and implications for drugs like Keytruda in treating melanoma.
EMA Conditional Marketing Authorizations: What You Need to Know
Explore the essentials of EMA Conditional Marketing Authorizations, focusing on drug XYZ for rare diseases and the implications for pharmaceutical companies.
EU HTA Regulation Impact: Effects on Rare Disease Drug Approvals & Market Access
This article examines how the EU HTA Regulation influences the approval and market access of rare disease drugs, focusing on Zolgensma for spinal muscular atrophy.
Solid Biosciences Receives European Orphan Drug Designation for SGT-003 Duchenne Muscular Dystrophy Treatment
Solid Biosciences secures European Commission orphan drug designation for SGT-003, advancing gene therapy development for Duchenne muscular dystrophy patients.
EU Pharmaceutical Legislation Reform: Impact on Orphan Drug Development & Market Exclusivity
This article examines how recent EU pharmaceutical legislation reforms affect orphan drug development and market exclusivity, shaping the future of rare disease therapies.
Crinetics Pharmaceuticals Receives EU Approval for PALSONIFY (Paltusotine), First Oral Daily Acromegaly Treatment
Crinetics Pharmaceuticals announces European Commission approval of PALSONIFY (paltusotine), the first once-daily oral therapy for acromegaly in adults.
EU Pharmaceutical Legislation: Impact on Orphan Drug Market Exclusivity
This article examines the implications of recent EU pharmaceutical legislation on the market exclusivity of orphan drugs, crucial for rare disease therapies.
EMA Issues Positive Opinion for Itvisma (Onasemnogene Abeparvovec) Gene Therapy for Spinal Muscular Atrophy
European Medicines Agency issues positive opinion for Itvisma, a one-time gene therapy for spinal muscular atrophy in infants and children.
EMA Recommends Approval of Plozasiran (Redemplo) for Rare Triglyceride Disorder FCS
European Medicines Agency recommends plozasiran (Redemplo) for marketing authorization to treat adults with familial chylomicronaemia syndrome in EU.